文献速递神经免疫

Elezanumab治疗复发型与进展型多发性硬化的随机双盲安慰剂对照研究

Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.
PubMed 文献 · Ann Neurol · 2025-07-23

RADIUS-R和RADIUS-P是两项2期试验,分别纳入复发型和进展型多发性硬化患者,随机接受Elezanumab 400mg、1800mg或安慰剂静脉注射每4周至48周。主要终点总体应答评分(ORS)在两项研究中均未达到,Elezanumab耐受性良好,严重不良事件发生率组间相似。

要点

  • Elezanumab在复发型和进展型MS中均未达到主要终点ORS。
  • Elezanumab耐受性良好,严重不良事件发生率与安慰剂相似。
  • 常见不良事件包括跌倒、尿路感染、头痛等。

核心结论

  • Elezanumab安全且耐受性良好,但在复发型和进展型MS中均未达到主要终点。

研究设计与样本

  • RADIUS-R和RADIUS-P为2期试验,分别针对复发型和进展型MS。
  • RADIUS-R纳入208例,随机接受Elezanumab 400mg(n=69)、1800mg(n=69)或安慰剂(n=70)。
  • RADIUS-P纳入123例,随机接受Elezanumab 400mg(n=40)、1800mg(n=40)或安慰剂(n=43)。
  • 给药方式为静脉注射每4周至第48周。

主要发现

  • RADIUS-R中Elezanumab 400mg组平均ORS为-0.2(效应量-0.2),1800mg组为-0.2(效应量-0.2)。
  • RADIUS-P中Elezanumab 400mg组平均ORS为0.0(效应量0.0),1800mg组为0.1(效应量0.1)。
  • 两项研究中严重不良事件发生率在各治疗组间相似。
  • RADIUS-R和RADIUS-P中发生率≥10%的不良事件包括跌倒、尿路感染、头痛;RADIUS-P还包括疲乏、输注相关反应和肌无力。

关键数值与推荐

  • 主要终点为平均总体应答评分(ORS)。
  • Elezanumab剂量为400mg或1800mg静脉注射每4周至第48周。

临床怎么用

  • Elezanumab虽安全耐受,但未达到主要疗效终点,不支持其用于复发型或进展型MS的进一步开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Elezanumab is a monoclonal antibody that binds repulsive guidance molecule a (RGMa), an inhibitor of central nervous system regeneration after inflammation or injury. The aim was to assess the safety and efficacy of elezanumab in relapsing and progressive forms of multiple sclerosis (MS). METHODS: RADIUS-R and RADIUS-P were phase 2 trials in relapsing (RADIUS-R) or progressive (RADIUS-P) MS. Participants were randomized to intravenous elezanumab 400mg, 1800mg, or placebo every 4 weeks through week 48. The primary endpoint was the mean Overall Response Score (ORS). RESULTS: In RADIUS-R, 208 participants received elezanumab 400mg (n = 69), elezanumab 1800mg (n = 69), or placebo (n = 70). In RADIUS-P, 123 participants received elezanumab 400mg (n = 40), elezanumab 1800mg (n = 40), or placebo (n = 43). The primary endpoint of ORS was not met in either study. For RADIUS-R, mean ORS was -0.2 with effect size of -0.2 for elezanumab 400mg and -0.2 with effect size of -0.2 for elezanumab 1800mg. For RADIUS-P, mean ORS was 0.0 with effect size of 0.0 for elezanumab 400mg and 0.1 with effect size of 0.1 for elezanumab 1800mg. Elezanumab was well tolerated; the rate of serious adverse events was similar across treatment groups in both studies. Adverse events with ≥10% of elezanumab population were falls, urinary tract infections, headaches in RADIUS-R and RADIUS-P, and also fatigue, infusion-related reactions, and muscular weakness in RADIUS-P. INTERPRETATION: Elezanumab was safe and well tolerated, but did not meet the primary endpoint in either study. ANN NEUROL 2025;98:590-602.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Cree BAC, Freedman MS, Gold M, et al. Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis. Ann Neurol. 2025. PMID: 40698976. doi:10.1002/ana.27262

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。